Treatment of Recurrent Bladder Cancer With Dendritic Cells
NCT ID: NCT04184232
Last Updated: 2021-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
17 participants
INTERVENTIONAL
2019-07-01
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells
NCT05108077
Immunological Response of Bladder Cancer Patients Under BCG
NCT04806178
Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
NCT06732531
Clinical Investigation of the Multi4 System
NCT06136312
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
NCT00234039
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dendritic cells
Patients with the recurrent bladder cancer receiving standard treatment and autologous dendritic cells
Dendritic cells
Autologous dendritic cells primed with muc-1/wt-1 peptides
Standard treatment according to the Clinical protocols
Standard treatment of bladder cancer according to the Clinical protocols
Control
Patients with the recurrent bladder cancer receiving standard treatment
Standard treatment according to the Clinical protocols
Standard treatment of bladder cancer according to the Clinical protocols
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dendritic cells
Autologous dendritic cells primed with muc-1/wt-1 peptides
Standard treatment according to the Clinical protocols
Standard treatment of bladder cancer according to the Clinical protocols
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient who require repetitive transurethral resection;
* Expression of muc-1/wt-1 by the tumor;
* EGOC 0-3;
Exclusion Criteria
* pregnancy/lactation;
* chronic infections, including hepatitis B/C, tuberculosis, HIV
18 Years
85 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Belarusian State Medical University
OTHER
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrei Hancharou, Dr
Role: STUDY_DIRECTOR
Director, the Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Alexander V Prokharau, Dr
Role: STUDY_DIRECTOR
Head of the chair, Belarusian State Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Minsk, , Belarus
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IBCE_DC1(BLAD)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.